Company profile for Verve Therapeutics

NEW Drugs in Dev.: 5
PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide. Verve brings together two of the biggest breakthroughs in 21st century biomedicine — human genetic analysis and gene editing — to realize a new future, one of longevity and vitality for tens of...
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide. Verve brings together two of the biggest breakthroughs in 21st century biomedicine — human genetic analysis and gene editing — to realize a new future, one of longevity and vitality for tens of millions of people worldwide at risk of coronary artery disease.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
215 First Street, Suite 440 Cambridge, MA 02142
Telephone
Telephone
(617) 603-0070
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/lilly-completes-acquisition-of-verve-therapeutics-to-advance-one-time-treatments-for-people-with-high-cardiovascular-risk-302513948.html

PR NEWSWIRE
25 Jul 2025

https://www.prnewswire.com/news-releases/lilly-and-verve-announce-expiration-of-verve-tender-offer-302513075.html

PR NEWSWIRE
24 Jul 2025

https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-nears-13-billion-deal-gene-editing-biotech-verve-therapeutics-ft-2025-06-16/

REUTERS
17 Jun 2025

https://www.fiercebiotech.com/biotech/verves-second-swing-pcsk9-editing-yields-clean-safety-profile-teeing-lilly-opt-decision

FIERCE BIOTECH
14 Apr 2025

https://www.fiercebiotech.com/biotech/vertex-axes-verve-gene-editing-pact-amid-shift-rd-priorities

FIERCE BIOTECH
28 Feb 2025

https://www.biopharmadive.com/news/verve-102-first-dosing-pcsk9-base-editing/715363/

BIOPHARMADIVE
08 May 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty